摘要本文将战略性新兴生物医药产业——生物类似物作为研究对象,在Web of Science的SCI数据库中以2004—2013年全球范围内该领域的研究论文做数据来源,通过信息可视化软件CiteSpace II绘制知识图谱,了解生物类似物研究领域的基本状况、研究热点和前沿,提出现阶段我国生物类似物的发展与政策构建建议。
Abstract：Through a visualized software CiteSpace II to draw scientometric maps,this paper focuses on the biosimilar researches in the bio-medical industry,and analyzes the articles in the Web of Science database from 2004 to 2013,thereby understanding the basic situation,research hot topics and future development in biosimilar field.Finally,associated with current situations in China,this paper proposes specific policy construction strategies for upgrading the biosimilar development.
陈名,邵蓉. 生物类似物研究领域的知识图谱分析及其对我国政策启示[J]. 中国科技论坛, 2014(11): 144-148.
Chen Ming,Shao Rong. Biosimilars Researches Based on a Scientometric Map Analysis and Its Political Implications. , 2014(11): 144-148.
[1]Chen C.CiteSpace II:Detecting and Visualizing Emerging Trends and Transient Patterns in Scientific Literature[J].Journal of the American Society for Information Science and Technology,2006,57(3):359-377. [2]Mellstedt H,Niederwieser D,Ludwig H.The Challenge of Biosimilars[J].Annals of oncology,2008,19(3):411-419. [3]Woodcock J,Griffin J,Behrman R,et al.The FDA's Assessment of Follow-on Protein Products:a Historical Perspective[J].Nature Reviews Drug Discovery,2007,6(6):437-442. [4]Casadevall N,Nataf J,Viron B,et al.Pure Red-cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin[J].New England Journal of Medicine,2002,346(7):469-475. [5]Schellekens H.Factors Influencing the Immunogenicity of Therapeutic Proteins[J].Nephrology Dialysis Transplantation,2005,20(suppl 6):vi3-vi9. [6]钱万强,陈涛,江海燕.基于文献计量学的国内外干细胞研究热点分析[J].中国科技论坛,2012, (2):152-159. [7]Schellekens H.Biosimilar Epoetins:How Similar are They[J].Eur J Hosp Pharm,2004,3:43-7. [8]Roger S D.Biosimilars:How Similar or Dissimilar are They?(Review Article)[J].Nephrology,2006,11(4):341-346. [9]Schneider C K,Kalinke U.Toward Biosimilar Monoclonal Antibodies[J].Nature Biotechnology,2008,26(9):985-990. [10]World Health Organization.Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)[J/OL].(2014-01-20).http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf [11]European Medicines Agency.Guideline on Similar Biological Medicinal Products(CHMP/437/04)[J/OL].(2014-01-22).http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf [12]U.S Food and Drug Administration.Part 2:Biosimilar Biological Products[EB/OL].(2014/01/22).http://www.fda.gov/AboutFDA/Transparency/Basics/ucm364686.htm [13]常卫红,王军志.关于生物仿制药药学研究问题的思考[J].中国药事,2008,22(1):23-25. [14]Schiestl M.A Biosimilar Industry View on the Implementation of the WHO Guidelines on Evaluating Similar Biotherapeutic Products[J].Biologicals,2011,39(5):297-299. [15]蒋舒寒.欧美生物仿制药的发展现状综述[J].中国医药指南,2010,8(27).
2014, 
